Why bioscience Is Trending Today?

**Avid Headlines:** - **Music:** Boypee, Hyce & Brown Joel released "Ogechi" featuring Davido. - **Sports:** David Adeleye reacted to Moses Itauma fight rumors, while Connor McDavid and Stuart Skinner attended a ladies' Halloween party. - **Business:** Novartis announced a $12B acquisition of Avidity Biosciences, with Halper Sadeh LLC investigating the fairness of the sale. - **Education:** Daniel David, Romania's Minister of Education, promised systemic measures to combat functional illiteracy and addressed teacher protests. - **Politics:** David Beckham supported a company investing in Bitcoin, while David Cantero discussed Princess Leonor. - **Entertainment:** Lily Allen and David Harbour listed their Brooklyn home following Allen's tell-all album, with Allen's new music targeting Harbour and his lover.

Avidity Biosciences is in the spotlight today, with Novartis announcing a $12 billion cash deal to acquire the biotech company, sending Avidity's stock soaring. The acquisition aims to expand Novartis' neuroscience portfolio. Meanwhile, David Eby, British Columbia's Attorney General, confirms that the province's anti-tariff ads targeting Americans will proceed. In the music world, Lily Allen's new album, seemingly detailing her divorce from David Harbour, has sparked interest, with fans eager to learn more about their relationship timeline. Additionally, David Lammy, the UK's Justice Secretary, faces questions in the Commons after the arrest of a migrant sex offender who was mistakenly freed from jail.

Novartis, a leading Swiss drugmaker, has agreed to acquire Avidity Biosciences, a US-based biotech firm specializing in RNA therapies for rare diseases, in a deal valued at approximately $12 billion. The acquisition, which is expected to boost Novartis' pipeline in rare diseases, involves Novartis paying around $70 per share for Avidity Biosciences.

Cogent Biosciences (NASDAQ:COGT) experiences significant trading volume surge following analyst upgrade.

Cogent Biosciences (NASDAQ:COGT) sees increased price targets from analysts at Leerink and Jefferies, with the latter raising its target to $28.00. The company recently priced an upsized capital raise of $200M via a stock offering, despite a temporary stock dip following the announcement. Analysts highlight the potential of Cogent's chronic immune disorder drug to become a blockbuster.